首页>
外国专利>
Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples
Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples
展开▼
机译:癌症患者选择使用基于血液的样品进行质谱分析来治疗药物
展开▼
页面导航
摘要
著录项
相似文献
摘要
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a solid epithelial tumor cancer patient is likely to benefit from a therapeutic agent or a combination of therapeutic agents targeting agonists of the receptors, receptors or proteins involved in MAPK (mitogen-activated protein kinase) pathways or the PKC (protein kinase C) pathway upstream from or at Akt or ERK/JNK/p38 or PKC, such as therapeutic agents targeting EGFR and/or HER2. The methods also provide the ability to determine whether the cancer patient is likely to benefit from the combination of a therapeutic agent targeting EFGR and a therapeutic agent targeting COX2; or whether the cancer patient is likely to benefit from the treatment with an NF-κB inhibitor.
展开▼